Cargando…
The ClC-2 Chloride Channel Activator, Lubiprostone, Improves Intestinal Barrier Function in Biopsies from Crohn’s Disease but Not Ulcerative Colitis Patients
The prostone analog, lubiprostone, is approved to manage constipation-predominant irritable bowel syndrome. Lubiprostone also protects intestinal mucosal barrier function in animal models of colitis. The aim of this study was to determine if lubiprostone improves barrier properties in isolated colon...
Autores principales: | Park, Young Su, Kang, Sang Bum, Marchelletta, Ronald R., Penrose, Harrison M., Ruiter-Visser, Roos, Jung, Barbara, Docherty, Michael J., Boland, Brigid S., Sandborn, William J., McCole, Declan F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053841/ https://www.ncbi.nlm.nih.gov/pubmed/36986672 http://dx.doi.org/10.3390/pharmaceutics15030811 |
Ejemplares similares
-
A comparison of linaclotide and lubiprostone dosing regimens on ion transport responses in human colonic mucosa
por: Kang, Sang Bum, et al.
Publicado: (2015) -
Long-Term Safety and Effectiveness of Lubiprostone, a Chloride Channel (ClC-2) Activator, in Patients with Chronic Idiopathic Constipation
por: Lembo, Anthony J., et al.
Publicado: (2011) -
Short Chain Fatty Acids Effect on Chloride Channel ClC-2 as a Possible Mechanism for Lubiprostone Intestinal Action
por: Catalán, Marcelo A., et al.
Publicado: (2020) -
ClC chloride channels
por: Mindell, Joe, et al.
Publicado: (2001) -
Chloride Channelopathies of ClC-2
por: Bi, Miao Miao, et al.
Publicado: (2013)